Melanoma Research Alliance

Melanoma Research Alliance

Close: Nov 7, 2025

Pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment. Owner is soliciting proposals that address the gap in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and patients with melanoma). Successful proposals have the potential of applying important basic and preclinical discoveries to the near-term development of clinical trials and studies impacting melanoma detection, prevention, diagnosis, and/or treatment. Proposals for clinical studies testing well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline with milestones. IRB approval is not required at the time of application but is required before initial payments are made to an awarded proposal.

Melanoma Research Alliance

Close: Apr 10, 2026

Aim to accelerate the development of new approaches and technologies in cellular therapy and vaccine therapy specifically for acral and/or uveal melanoma. Proposals on GNAQ/11 related melanomas are also allowed. This RFP will support preclinical, pre-IND development stage, and clinical-stage studies focused on advancing cellular or vaccine-based therapeutic approaches that have the potential to improved treatment strategies for patients with acral or uveal melanoma.

Melanoma Research Alliance

Close: Feb 3, 2026

The RFP aims to support clinical validation studies or phase I clinical trials using new or improved imaging technologies, biomarkers, monitoring algorithms, diagnostic or screening tests, or devices. Studies proposing the use of technologies that are easily scalable are encouraged.